Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Duration of Therapy × Clear all
NCT00097929 2017-04-07

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Merck Sharp & Dohme LLC

Phase 2 Completed
18 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Merck Sharp & Dohme LLC

Phase 2 Completed
74 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡